Shulamiet Wittebol

2.3k citations

33 papers · 791 indexed · h-index 15

Hematology top 2%
- Multiple Myeloma Research and Treatments 19
Genetics top 10%
- Chronic Lymphocytic Leukemia Research 9
Oncology top 10%
- Cancer Treatment and Pharmacology 11
- Peptidase Inhibition and Analysis 4
Pathology and Forensic Medicine top 10%
- Lymphoma Diagnosis and Treatment 8
Molecular Biology
- Cancer therapeutics and mechanisms 5
- Protein Degradation and Inhibitors 4
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 3

Co-authors: Pieter Sonneveld Sonja Zweegman Rianne Ammerlaan Henk M. Lokhorst M. Ronald Schaafsma Harm Sinnige René van der Griend Fabian Termorshuizen
Cited by: Hematology Genetics Oncology
Journals: Journal of Clinical Oncology (2 papers)Blood (13 papers)Cancer Research (1 paper)
Partner nations: Netherlands United States Belgium

In The Last Decade

Shulamiet Wittebol

31 papers receiving 780 citations

Peers

Countries citing papers authored by Shulamiet Wittebol

Since Specialization

Citations

This map shows the geographic impact of Shulamiet Wittebol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shulamiet Wittebol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shulamiet Wittebol more than expected).

Fields of papers citing papers by Shulamiet Wittebol

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shulamiet Wittebol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shulamiet Wittebol. The network helps show where Shulamiet Wittebol may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Shulamiet Wittebol, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Shulamiet Wittebol Line = papers co-authored together Shulamiet Wittebol links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia Leukemia & lymphoma ·Fie Juhl Vojdeman,Sarah E. M. Herman,Nikolai Kirkby,Adrian Wiestner,Mars B. van ’t Veer,Geir E. Tjønnfjord,Maija Itälä‐Remes,Eva Kimby,Mohammed Farooqui,Aaron Polliack,Ka Lung Wu,Jeanette K. Doorduijn,Wendimagegn Alemayehu,Shulamiet Wittebol,Tomáš Kozák,Jan Walewski,Martine C. J. Abrahamse-Testroote,Marinus H. J. van Oers,Christian H. Geisler,Carsten Utoft Niemann	2017	10
2	Phase I/II Trial of Weekly Escalated Dose Bortezomib Combined with Lenalidomide and Dexamethasone in Patients in First Relapse or Primary Refractory Disease after First Line Therapy for Multiple Myeloma Blood ·Annemiek Broijl,Marie José Kersten,Wendim Ghidey Alemayehu,Mark‐David Levin,Okke de Weerdt,Edo Vellenga,Ellen Meijer,Shulamiet Wittebol,Rosita Ghiraw-Visser,Marian Stevens‐Kroef,Berna Beverloo,Gerard M.J. Bos,Pierre W. Wijermans,Henk M. Lokhorst,Pieter Sonneveld	2014	2
3	Thalidomide Combined With High Dose Melphalan Improves Event Free and Overall Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-50 Trial Blood ·Henk M. Lokhorst,Bronno van der Holt,Sonja Zweegman,Edo Vellenga,Sandra Croockewit,Marinus H. J. van Oers,Peter A. von dem Borne,Pierre W. Wijermans,M. Ronald Schaafsma,Okke de Weerdt,Shulamiet Wittebol,Michel Delforge,Gerard M.J. Bos,Harm Sinnige,Marinus van Marwijk-Kooy,Peter Joosten,Monique C. Minnema,Rianne Ammerlaan,Pieter Sonneveld	2013	1
4	Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study) Blood ·Inger S. Nijhof,Sonja Zweegman,Mark‐David Levin,Harry R. Koene,Aart Beeker,Andries C. Bloem,Gerard M.J. Bos,Laura M. Faber,Saskia K. Klein,Evert-Jan F. M. de Kruijf,Ellen van der Spek,Shulamiet Wittebol,Jeroen F. van Velzen,Berris van Kessel,Tuna Mutis,Pieter Sonneveld,Henk M. Lokhorst,Niels W.C.J. van de Donk	2013	1
5	Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial Annals of Hematology ·(unknown),S. Verelst,Fabian Termorshuizen,Carin A. Uyl‐de Groot,M. Ronald Schaafsma,A. H. M. Ammerlaan,Shulamiet Wittebol,Harm Sinnige,Sonja Zweegman,Marinus van Marwijk Kooy,René van der Griend,H M Lokhorst,Pieter Sonneveld,P. Wijermans	2011	29
6	The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies Blood Cancer Journal ·Michael S. van der Veer,Michel de Weers,Berris van Kessel,Joost M. Bakker,Shulamiet Wittebol,Paul W.H.I. Parren,H M Lokhorst,Tuna Mutis	2011	81
7	Analysis of Efficacy and Prognostic Factors of Lenalidomide Treatment as Part of a Dutch Compassionate Use Program Clinical Lymphoma Myeloma & Leukemia ·Evelien Kneppers,Henk M. Lokhorst,Corien Eeltink,Gerwin Huls,Marie José Kersten,Jan Koedam,Monique C. Minnema,Marinus H. J. van Oers,Reinier Raymakers,M. Ronald Schaafsma,Edo Vellenga,Pierre W. Wijermans,Shulamiet Wittebol,Pieter Sonneveld,Sonja Zweegman	2010	16
8	Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study Journal of Clinical Oncology ·Pierre W. Wijermans,M. Ronald Schaafsma,Fabian Termorshuizen,Rianne Ammerlaan,Shulamiet Wittebol,Harm Sinnige,Sonja Zweegman,Marinus van Marwijk Kooy,René van der Griend,Henk M. Lokhorst,Pieter Sonneveld	2010	189
9	Improved Myeloma Targeting by Combination of the Human Anti-CD38 Antibody Daratumumab with Lenalidomide and Bortezomib Blood ·Michael S. van der Veer,Michel de Weers,Berris van Kessel,Joost M. Bakker,Shulamiet Wittebol,Paul W.H.I. Parren,Henk M. Lokhorst,Tuna Mutis	2010	2
10	Effect of Thalidomide with Melphalan and Prednisone on Health-Related Quality of Life (HRQoL) in Elderly Patients with Newly Diagnosed Multiple Myeloma: A Prospective Analysis In a Randomized Trial Blood ·S. Verelst,Fabian Termorshuizen,CA Uyl‐de Groot,Martyn Ronald Schaafsma,Rianne Ammerlaan,Shulamiet Wittebol,Harm Sinnige,Sonja Zweegman,Marinus van Marwijk Kooy,René van der Griend,H M Lokhorst,Pieter Sonneveld,P. Wijermans	2010	4
11	On the Added Value of Baseline FDG-PET in Malignant Lymphoma Molecular Imaging and Biology ·Henriëtte M. E. Quarles van Ufford,Otto S. Hoekstra,Marie de Haas,Rob Fijnheer,Shulamiet Wittebol,Bianca Tieks,Mark H.H. Kramer,John de Klerk	2009	20
12	A Dutch Family with Hb Debrousse: Severe Anemia After Parvovirus B19 Infection Hemoglobin ·Peter van Balen,Merel van Wijnen,Paul H.G. Hogeman,Shulamiet Wittebol	2009	0
13	In vivo Dynamics of Stable Chronic Lymphocytic Leukemia Inversely Correlate with Somatic Hypermutation Levels and Suggest No Major Leukemic Turnover in Bone Marrow Cancer Research ·Rogier van Gent,Arnon P. Kater,Sigrid A. Otto,Annelieke Jaspers,José A. M. Borghans,Nienke Vrisekoop,Mariëtte A.T. Ackermans,An F.C. Ruiter,Shulamiet Wittebol,Eric Eldering,Marinus H. J. van Oers,Kiki Tesselaar,Marie José Kersten,Frank Miedema	2008	48
14	Melphalan + Prednisone Versus Melphalan + Prednisone + Thalidomide in Induction Therapy for Multiple Myeloma in Elderly Patients: Final Analysis of the Dutch Cooperative Group HOVON 49 Study Blood ·P. Wijermans,M. Ronald Schaafsma,Yvette van Norden,Rianne Ammerlaan,Shulamiet Wittebol,Harm Sinnige,Sonja Zweegman,M. van Marwijk Kooi,René van der Griend,H M Lokhorst,Pieter Sonneveld	2008	35
15	Final Analysis of HOVON-50 Randomized Phase III Study on the Effect of Thalidomide Combined with Adriamycine, Dexamethasone (AD) and High Dose Melphalan (HDM) in Patients with Multiple Myeloma (MM) Blood ·Henk M. Lokhorst,Bronno van der Holt,Sonja Zweegman,Peter A. von dem Borne,Gerard M.J. Bos,Sandra Croockewit,Jan J. Cornelissen,Marinus van Oers,Martyn Ronald Schaafsma,Harm Sinnige,Michel Delforge,Okke de Weerdt,Pierre W. Wijermans,Shulamiet Wittebol,Edo Vellenga,Kon‐Siong G. Jie,Henriette W Berenschot,Marinus van Marwijk-Kooy,Pieter Sonneveld	2008	10
16	Pericardial involvement in a non-Hodgkin lymphoma patient: coregistered FDG-PET and CT imaging European Heart Journal ·Leo E. Weijs,Georgios Arsos,Henk J. Baarslag,Shulamiet Wittebol,John M. de Klerk	2007	19
17	High levels of serum prostate‐specific antigen due to PSA producing follicular non‐Hodgkin’s lymphoma European Journal Of Haematology ·Jan Jelrik Oosterheert,Leo M. Budel,Pieter Vos,Shulamiet Wittebol	2007	7
18	High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study Annals of Hematology ·Wendy Deenik,Bronno van der Holt,G. Verhoef,A Schattenberg,LF Verdonck,Simon Daenen,Pierre Zachée,Petra H.M. Westveer,Willem M. Smit,Shulamiet Wittebol,Harry C. Schouten,Bob Löwenberg,G. J. Ossenkoppele,Jan J. Cornelissen	2006	5
19	The impact of intensive antileukaemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to International Prognostic Scoring System risk groups British Journal of Haematology ·Margriet Oosterveld,Shulamiet Wittebol,W.A.J.G. Lemmens,Lambertus A. Kiemeney,Ashuman Çatik,Petra Muus,A Schattenberg,T.J.M. de Witte	2003	15
20	Factor VIII inhibitor in a patient with mild haemophilia A and an Asn⁶¹⁸→Ser mutation responsive to immune tolerance induction and cyclophosphamide British Journal of Haematology ·André J. Vlot,Shulamiet Wittebol,Paul Strengers,Ellen A.M. Turenhout,Jan Voorberg,H. Marijke van den Berg,Eveline P. Mauser‐Bunschoten	2002	19

About Shulamiet Wittebol

Shulamiet Wittebol is a scholar working on Hematology, Genetics and Oncology, having authored 33 papers that have together received 791 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (19 papers), Cancer Treatment and Pharmacology (11 papers), Chronic Lymphocytic Leukemia Research (9 papers), Lymphoma Diagnosis and Treatment (8 papers), Cancer therapeutics and mechanisms (5 papers), Protein Degradation and Inhibitors (4 papers), Peptidase Inhibition and Analysis (4 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). The work is most often cited by research in Hematology (493 citations), Genetics (159 citations) and Oncology (319 citations). Shulamiet Wittebol has collaborated with scholars based in Netherlands, United States and Belgium. Frequent co-authors include Pieter Sonneveld, Sonja Zweegman, Rianne Ammerlaan, Henk M. Lokhorst, M. Ronald Schaafsma, Harm Sinnige, René van der Griend, Fabian Termorshuizen, Marinus van Marwijk Kooy and Pierre W. Wijermans. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact